title: Prediction of improvement of ventricular function after revascularization. 18F-fluorodeoxyglucose single-photon emission computed tomography vs low-dose dobutamine echocardiography.
abstract: OBJECTIVE
  To compare assessment of myocardial flow and glucose metabolism by single-photon emission computed tomography (SPECT) with low-dose dobutamine echocardiography in predicting improvement in regional and global left ventricular function after coronary artery bypass grafting.
  
  
  RESULTS
  Thirty patients with regional wall motion abnormalities (mean ejection fraction 32 +/- 19%) were studied with low-dose dobutamine echocardiography (5 and 10 micrograms. kg-1 min-1) and thallium-201/ 18F-fluorodeoxyglucose(FDG) SPECT prior to surgery. For comparative analysis, a 13-segment model was used. Postoperative improvement was predicted if the echocardiogram showed that wall motion abnormalities were reversible during the dobutamine infusion and there was normal perfusion or relatively increased FDG uptake in perfusion defects (mismatch) in dyssynergic segments on SPECT. After surgery, ventricular function was reassessed. An echocardiogram was taken at the 3 month follow-up with the patient at rest. Regional wall motion had improved in 62/168 (37%) revascularized segments. In predicting functional outcome, low-dose dobutamine echocardiography reached a sensitivity of 89% and a specificity of 82%, with a positive predictive value of 74% and a negative predictive value of 93%, whereas for thallium-201/FDG SPECT these values were 84%, 86%, 78% and 90%, respectively. In patients with more than two viable segments on either technique, the wall motion score index, a surrogate of global ventricular function, improved significantly.
  
  
  CONCLUSIONS
  For the optimal prediction of functional outcome, combined assessment of flow and FDG imaging is needed. Both thallium-201/FDG SPECT and low-dose dobutamine echocardiography appear comparable and similarly accurate in predicting improvement of left ventricular function after surgical revascularization.
authors.affiliation: Thoraxcenter, University Hospital Rotterdam-Dijkzigt, The Netherlands.
authors.forename: J H
authors.initials: JH
authors.lastname: Cornel
authors.forename: J J
authors.initials: JJ
authors.lastname: Bax
authors.forename: P M
authors.initials: PM
authors.lastname: Fioretti
authors.forename: F C
authors.initials: FC
authors.lastname: Visser
authors.forename: A P
authors.initials: AP
authors.lastname: Maat
authors.forename: E
authors.initials: E
authors.lastname: Boersma
authors.forename: A
authors.initials: A
authors.lastname: van Lingen
authors.forename: A
authors.initials: A
authors.lastname: Elhendy
authors.forename: J R
authors.initials: JR
authors.lastname: Roelandt
mesh_terms: D000704:Analysis of Variance; D002316:Cardiotonic Agents; D016009:Chi-Square Distribution; D001026:Coronary Artery Bypass; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D004280:Dobutamine; D004452:Echocardiography; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D009204:Myocardial Revascularization; D011237:Predictive Value of Tests; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging*
chemical_list: D002316:Cardiotonic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D004280:Dobutamine; D003847:Deoxyglucose